Radhika Bansal
Overview
Explore the profile of Radhika Bansal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500453.
PMID: 40053892
No abstract available.
2.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401730.
PMID: 39965175
Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety,...
3.
Sidana S, Patel K, Peres L, Bansal R, Kocoglu M, Shune L, et al.
Blood
. 2024 Oct;
145(1):85-97.
PMID: 39365257
Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for...
4.
Khurana A, Rosenthal A, Mohty R, Gaddam M, Bansal R, Hathcock M, et al.
Blood Cancer J
. 2024 Aug;
14(1):136.
PMID: 39134524
No abstract available.
5.
Jain M, Spiegel J, Nastoupil L, Tamaresis J, Ghobadi A, Lin Y, et al.
J Clin Oncol
. 2024 Aug;
42(30):3581-3592.
PMID: 39094076
Purpose: Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known...
6.
Rees M, Mammadzadeh A, Bolarinwa A, Elhaj M, Bohra A, Bansal R, et al.
Blood Cancer J
. 2024 Jul;
14(1):122.
PMID: 39043638
Three classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed...
7.
Saifi O, Breen W, Lester S, Rule W, Stish B, Rosenthal A, et al.
Blood Adv
. 2024 Jul;
8(18):4877-4885.
PMID: 39028948
Unirradiated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who undergo anti-CD19 chimeric antigen receptor T-cell therapy (CART) have a predominant localized pattern of relapse, the significance of which is...
8.
Huang T, Bansal R, Ghosh S, Lee K, Chen Q, Tan C, et al.
Opt Lett
. 2024 Mar;
49(5):1281-1284.
PMID: 38426993
We report high-performance germanium-on-insulator (GeOI) waveguide photodetectors (WGPDs) for electronic-photonic integrated circuits (EPICs) operating at telecommunication wavelengths. The GeOI samples were fabricated using layer transfer and wafer-bonding techniques, and a...
9.
Bansal R, Vergidis P, Tosh P, Wilson J, Hathcock M, Khurana A, et al.
Transplant Cell Ther
. 2024 Feb;
30(4):455.e1-455.e7.
PMID: 38346643
Antibody titers and the potential need for immunization have not been formally studied in recipients of chimeric antigen receptor T cell therapy (CAR-T). Prior studies have shown that CD19-targeted CAR-T...
10.
Rejeski K, Wang Y, Hansen D, Iacoboni G, Bachy E, Bansal R, et al.
Blood Adv
. 2024 Jan;
8(8):1857-1868.
PMID: 38181508
Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can predispose for severe infectious complications. Current grading systems, such as the Common Terminology Criteria for Adverse...